Fundraising Fox

Vaccinex

OTC: VCNX

Rochester, US · Delaware corporation · 29 employees on LinkedIn · 1 known investors

Vaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.

BiotechHealthtechMedical Devices

Founders & leadership

MZ
Maurice Zauderer, Ph.D.Co-founder
MZ
Maurice ZaudererCo-founder
EEElizabeth Evans
Elizabeth EvansExecutive
ES
Ernest S. Smith Ph.D.Executive
JS
Jill SanchezExecutive
ES
Ernest S. SmithExecutive
RW
Raymond WatkinsExecutive
SE
Scott E. RoyerExecutive

Board

JB
Jacob B. FriebergBoard director
AD
Albert D. FriedbergBoard director
CB
Chrystyna Bedrij StecykBoard director
GE
Gerald E. Van StrydonckBoard director

Investors · 1

Polaris PartnersreportedBoston · $500K – $5Mvia Alan Crane · board

Funding

SEC filings, press & company announcements

$104.5M disclosed across 10 of 11 rounds · 2017–2025

▶$200.2KraisedSep 2024 · 8 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jacob B. FriebergDirector
  • Gerald E. Van StrydonckDirector
  • Albert D. FriedbergDirector
  • Maurice Zauderer, Ph.D.Director, Executive Officer
  • Elizabeth EvansExecutive Officer
  • Barbara YanniDirector
  • Ernest S. Smith Ph.D.Executive Officer
  • Jill SanchezExecutive Officer
  • Bala S. Manian Ph.D.Director
Offering amount
$9.2M
Amount sold
$200.2K
Sales commissions
$8.8K
Placement agents
Roth Capital Partners, LLC
First sale
Sep 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MofferedApr 2024 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Bala S. Manian, Ph.D.Director
  • Jacob B. FriebergDirector
  • Albert D. FriedbergDirector
  • Ernest S. Smith, Ph.D.Executive Officer
  • Gerald E. Van StrydonckDirector
  • Barbara YanniDirector
  • Maurice Zauderer, Ph.D.Director, Executive Officer
  • Jill SanchezExecutive Officer
  • Chrystyna Bedrij StecykDirector
  • Elizabeth EvansExecutive Officer
Offering amount
$1.5M
Finders' fees
$215K
Placement agents
A.G.P./Alliance Global Partners
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedApr 2024 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jill SanchezExecutive Officer
  • Maurice Zauderer, Ph.D.Director, Executive Officer
  • Barbara YanniDirector
  • Bala S. Manian, Ph.D.Director
  • Jacob B. FriebergDirector
  • Albert D. FriedbergDirector
  • Ernest S. Smith, Ph.D.Executive Officer
  • Elizabeth EvansExecutive Officer
  • Chrystyna Bedrij StecykDirector
  • Gerald E. Van StrydonckDirector
Offering amount
$2.5M
Amount sold
$1.2M
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedApr 2024 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Chrystyna Bedrij StecykDirector
  • Elizabeth EvansExecutive Officer
  • Jill SanchezExecutive Officer
  • Maurice Zauderer, Ph.D.Director, Executive Officer
  • Ernest S. Smith, Ph.D.Executive Officer
  • Gerald E. Van StrydonckDirector
  • Bala S. Manian, Ph.D.Director
  • Jacob B. FriebergDirector
  • Albert D. FriedbergDirector
  • Barbara YanniDirector
Offering amount
$3.5M
Amount sold
$1.8M
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedSep 2020 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Gerald E. Van StrydonckDirector
  • J. Jeffrey GoaterDirector
  • Bala S. ManianDirector
  • Chrystyna Bedrij StecykDirector
  • Barbara YannniDirector
  • Scott E. RoyerExecutive Officer
  • Raymond WatkinsExecutive Officer
  • Jacob B. FriebergDirector
  • Maurice ZaudererExecutive Officer, Director
  • Albert D. FriedbergDirector
  • Ernest S. SmithExecutive Officer
Offering amount
$2M
Amount sold
$2M
First sale
Sep 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8MraisedAug 2020 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Gerald E. Van StrydonckDirector
  • J. Jeffrey GoaterDirector
  • Barbara YannniDirector
  • Chrystyna Bedrij StecykDirector
  • Jacob B. FriebergDirector
  • Albert D. FriedbergDirector
  • Ernest S. SmithExecutive Officer
  • Bala S. ManianDirector
  • Maurice ZaudererExecutive Officer, Director
  • Raymond WatkinsExecutive Officer
  • Scott E. RoyerExecutive Officer
Offering amount
$8M
Amount sold
$8M
First sale
Aug 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedJul 2020 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Ernest S. SmithExecutive Officer
  • J. Jeffrey GoaterDirector
  • Alejandro M. BerlinDirector
  • Bala S. ManianDirector
  • Raymond WatkinsExecutive Officer
  • Scott E. RoyerExecutive Officer
  • Jacob B. FriebergDirector
  • Gerald E. Van StrydonckDirector
  • Barbara YanniDirector
  • Albert D. FriedbergDirector
  • Chrystyna Bedrij StecykDirector
  • Maurice ZaudererExecutive Officer, Director
Offering amount
$4M
Amount sold
$4M
First sale
Jul 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.5MraisedFeb 2020 · 5 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jacob B. FriebergDirector
  • Maurice ZaudererExecutive Officer, Director
  • Scott E. RoyerExecutive Officer
  • Raymond WatkinsExecutive Officer
  • Ernest S. SmithExecutive Officer
  • Barbara YanniDirector
  • J. Jeffrey GoaterDirector
  • Bala S. ManianDirector
  • Gerald E. Van StrydonckDirector
  • Alejandro M. BerlinDirector
  • Albert D. FriedbergDirector
Offering amount
$7.5M
Amount sold
$7.5M
First sale
Jan 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap
Imvax53 shared keywordsImvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.
Bioworld49 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Dynavax NASDAQ: DVAX www.dynavax.com47 shared keywordsDynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.
Vaxcyte40 shared keywordsVaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques. Its pipeline includes pneumococcal conjugate vaccines (VAX-31 and VAX-24) and early-stage candidates targeting Group A Strep and Shigella.

Companies competing with Vaccinex for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease - BioSpacebiospace.com · Dec 2025Vaccinex secures $60 million funding for Alzheimer’s drug development By Investing.cominvesting.com · Dec 2025Windtree offloads cardio pipeline, Vaccinex secures $60M funding in continued holiday shopping spreefiercebiotech.com · Dec 2025Vaccinex Raises $60 Million for Phase 2b Alzheimer’s Trialhealthtechnologyinsights.com · Dec 2025

Frequently asked questions

What does Vaccinex do?
Vaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
Who founded Vaccinex?
Vaccinex was founded by Maurice Zauderer, Ph.D., Maurice Zauderer.
Who are Vaccinex's investors?
Vaccinex's investors include Polaris Partners.
How much funding has Vaccinex raised?
Vaccinex has disclosed $104.5M raised across 10 of its 11 known rounds.
Where is Vaccinex headquartered?
Vaccinex is headquartered in Rochester, US.